205 related articles for article (PubMed ID: 34492133)
21. Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies.
Zhang JM; Genois MM; Ouyang J; Lan L; Zou L
Mol Cell; 2021 Mar; 81(5):1027-1042.e4. PubMed ID: 33453166
[TBL] [Abstract][Full Text] [Related]
22. The telomere-associated homeobox-containing protein TAH1/HMBOX1 participates in telomere maintenance in ALT cells.
Feng X; Luo Z; Jiang S; Li F; Han X; Hu Y; Wang D; Zhao Y; Ma W; Liu D; Huang J; Songyang Z
J Cell Sci; 2013 Sep; 126(Pt 17):3982-9. PubMed ID: 23813958
[TBL] [Abstract][Full Text] [Related]
23. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies.
Gocha AR; Nuovo G; Iwenofu OH; Groden J
Am J Pathol; 2013 Jan; 182(1):41-8. PubMed ID: 23260199
[TBL] [Abstract][Full Text] [Related]
24. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1.
Wu G; Jiang X; Lee WH; Chen PL
Cancer Res; 2003 May; 63(10):2589-95. PubMed ID: 12750284
[TBL] [Abstract][Full Text] [Related]
25. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
26. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.
Fasching CL; Bower K; Reddel RR
Cancer Res; 2005 Apr; 65(7):2722-9. PubMed ID: 15805271
[TBL] [Abstract][Full Text] [Related]
27. Molecular and cellular evidence for the alternative lengthening of telomeres (ALT) mechanism in chicken.
O'Hare TH; Delany ME
Cytogenet Genome Res; 2011; 135(1):65-78. PubMed ID: 21822009
[TBL] [Abstract][Full Text] [Related]
28. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer.
Mori JO; Keegan J; Flynn RL; Heaphy CM
J Clin Pathol; 2024 Jan; 77(2):82-86. PubMed ID: 37890990
[TBL] [Abstract][Full Text] [Related]
29. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
[TBL] [Abstract][Full Text] [Related]
30. Nuclear body phase separation drives telomere clustering in ALT cancer cells.
Zhang H; Zhao R; Tones J; Liu M; Dilley RL; Chenoweth DM; Greenberg RA; Lampson MA
Mol Biol Cell; 2020 Aug; 31(18):2048-2056. PubMed ID: 32579423
[TBL] [Abstract][Full Text] [Related]
31. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
Henson JD; Hannay JA; McCarthy SW; Royds JA; Yeager TR; Robinson RA; Wharton SB; Jellinek DA; Arbuckle SM; Yoo J; Robinson BG; Learoyd DL; Stalley PD; Bonar SF; Yu D; Pollock RE; Reddel RR
Clin Cancer Res; 2005 Jan; 11(1):217-25. PubMed ID: 15671549
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic herpesvirus KSHV triggers hallmarks of alternative lengthening of telomeres.
Lippert TP; Marzec P; Idilli AI; Sarek G; Vancevska A; Bower M; Farrell PJ; Ojala PM; Feldhahn N; Boulton SJ
Nat Commun; 2021 Jan; 12(1):512. PubMed ID: 33479235
[TBL] [Abstract][Full Text] [Related]
33. Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins.
Jiang WQ; Zhong ZH; Nguyen A; Henson JD; Toouli CD; Braithwaite AW; Reddel RR
J Cell Biol; 2009 Jun; 185(5):797-810. PubMed ID: 19468068
[TBL] [Abstract][Full Text] [Related]
34. SLX4IP promotes RAP1 SUMOylation by PIAS1 to coordinate telomere maintenance through NF-κB and Notch signaling.
Robinson NJ; Miyagi M; Scarborough JA; Scott JG; Taylor DJ; Schiemann WP
Sci Signal; 2021 Jun; 14(689):. PubMed ID: 34187905
[TBL] [Abstract][Full Text] [Related]
35. Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body.
Nabetani A; Yokoyama O; Ishikawa F
J Biol Chem; 2004 Jun; 279(24):25849-57. PubMed ID: 15075340
[TBL] [Abstract][Full Text] [Related]
36. Single-Molecule Telomere Assay via Optical Mapping (SMTA-OM) Can Potentially Define the ALT Positivity of Cancer.
Raseley K; Jinwala Z; Zhang D; Xiao M
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372458
[TBL] [Abstract][Full Text] [Related]
37. HP1-mediated formation of alternative lengthening of telomeres-associated PML bodies requires HIRA but not ASF1a.
Jiang WQ; Nguyen A; Cao Y; Chang AC; Reddel RR
PLoS One; 2011 Feb; 6(2):e17036. PubMed ID: 21347226
[TBL] [Abstract][Full Text] [Related]
38. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
[TBL] [Abstract][Full Text] [Related]
39. Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof.
Claude E; Decottignies A
Curr Opin Genet Dev; 2020 Feb; 60():1-8. PubMed ID: 32114293
[TBL] [Abstract][Full Text] [Related]
40. The telomere maintenance mechanism spectrum and its dynamics in gliomas.
Kim S; Chowdhury T; Yu HJ; Kahng JY; Lee CE; Choi SA; Kim KM; Kang H; Lee JH; Lee ST; Won JK; Kim KH; Kim MS; Lee JY; Kim JW; Kim YH; Kim TM; Choi SH; Phi JH; Shin YK; Ku JL; Lee S; Yun H; Lee H; Kim D; Kim K; Hur JK; Park SH; Kim SK; Park CK
Genome Med; 2022 Aug; 14(1):88. PubMed ID: 35953846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
